昂利康：与亚飞生物、亲合力签署授权许可协议 公司将获得IMD-1005药物分子在中国的独家权益

Core Viewpoint - The company, Anglikang, has signed a licensing agreement with Aifei Biopharmaceutical and Qinhuli Biopharmaceutical, granting it exclusive rights to develop, manufacture, and commercialize the drug molecule IMD-1005 in China, including mainland China, Hong Kong, Macau, and Taiwan [1] Group 1 - The company will make an initial payment of 150 million RMB to Aifei and Qinhuli, with potential milestone payments to Qinhuli not exceeding 620 million RMB for research and sales [1] - The company is also obligated to pay a sales share of 12.8% to Qinhuli during the sales revenue sharing period [1] - IMD-1005 is an innovative tumor microenvironment-activated IgG1 subtype antibody targeting CD47, which is expected to provide new immunotherapy options for cancer patients [1]